Schor Chen 4

What Happened

• Schor Chen, President & CEO and a director of Adicet Bio, received an award of 468,555 derivative shares on 2026-03-25. The Form 4 reports the acquisition price as $0.00, indicating a compensation grant rather than an open-market purchase or sale. The award is listed as a derivative/award (reporting code A).

Key Details

• Transaction date: 2026-03-25; Form filed: 2026-03-27 (timely filing).
• Amount: 468,555 shares awarded; reported price: $0.00.
• Vesting: per footnote, 1/48th of the shares vest on each of the next 48 monthly anniversaries, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: describes monthly vesting schedule (1/48th each month for 48 months).
• No indication in the filing of immediate sale, tax withholding, or a 10b5-1 plan.

Context

• This is a compensation award (likely restricted stock units or similar derivative) that vests over four years; such grants are common for executives and reflect compensation, not a direct market purchase. The Form 4 does not state a dollar value — the eventual economic value will depend on Adicet Bio’s share price at vesting.